CBX

Dizal Pharma has initiated a phase 2 study ( CTR20240120 ) of DZD8586, a fully blood-brain barrier (BBB) penetrable LYN/BTK dual inhibitor, for the treatment of CLL/SLL in China. The sponsor aims to enroll an estimated 155 patients with rr-CLL/SLL. The patients in the three groups will receive DZD8586 at doses of 25 mg, 75 mg, and 100 mg. https://doi.org/10.1038/nchembio.502 Recently, Dizal highlighted various results from preclinical and clinical studies of DZD8586. As DZD8586 inhibits both LYN and BTK simultaneously, it demonstrated anti-proliferative effects in cell lines expressing C481X and pirtobrutinib resistance mutations . Additionally, DZD8586 exhibited potent cell growth inhibition and induced cell death in a variety of DLBCL cell lines. Moreover, it demonstrated profound tumor growth inhibition in both CNS tumor models, attributed to its specific blood-brain barrier (BBB) penetration. DZD8586 demonstrated consistent results in the early human study . The dose escalation a